Anti-Legumain antibody

Cat.#: 101248

Special Price 145.0 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Anti-Legumain antibody
  • Documents
  • Description
    Rabbit polyclonal to Legumain
  • Tested applications
    WB, IP
  • Species reactivity
    Sus scrofa (Pig) Legumain / LGMN
  • Alternative names
    AEP antibody; LGMN1 antibody; PRSC1 antibody; AEP antibody; Prsc1 antibody; AI746452 antibody; AU022324 antibody; AEP antibody; AEP antibody; AI746452 antibody; AU022324 antibody; Legumain antibody; Legumain antibody; Lgmn antibody; LGMN antibody; LGMN1 antibody; Prsc1 antibody; PRSC1 antibody
  • Immunogen
  • Isotype
    Rabbit IgG
  • Preparation
    Produced in rabbits immunized with purified, recombinant Sus scrofa (Pig) Legumain / LGMN (XP_001927117.4; Met1-Tyr433). Legumain / LGMN specific IgG was purified by Sus scrofa (Pig) Legumain / LGMN affinity chromatography.
  • Clonality
    Polyclonal
  • Formulation
    0.2 μm filtered solution in PBS
  • Storage instructions
    This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
    Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
  • Applications

    WB: 2-10 μg/ml

    IP: 4-6 μg/mg of lysate

  • Validations

    Legumain / LGMN Antibody, Rabbit PAb, Antigen Affinity Purified, Western blot

    Legumain / LGMN Antibody, Rabbit PAb, Antigen Affinity Purified, Western blot

    Legumain / LGMN Antibody, Rabbit PAb, Antigen Affinity Purified, Immunoprecipitation

    Legumain / LGMN Antibody, Rabbit PAb, Antigen Affinity Purified, Immunoprecipitation

    Immunochemical staining of human GJA1 in mouse heart with rabbit polyclonal antibody (0.05 µg/mL, formalin-fixed paraffin embedded sections).

  • Background
    The Mammalian Legumain, also known as LGMN, also called asparaginyl endopeptidase (AEP), is a cysteine protease belonging to peptidase family C13 with a strict specificity for hydrolysis of asparaginyl bonds. Known previously only from plants and invertebrates, Legumain is discovered as a lysosomal endopeptidase in mammals. Mammalian Legumain is a cysteine endopeptidase, inhibited by iodoacetamide and maleimides, but unaffected by compound E64. The Mammalian Legumain is involved in the processing of bacterial peptides and endogenous proteins for MHC class II presentation in the lysosomal/endosomal systems. Legumain has been observed to be highly expressed in several types of solid tumors. It was demonstrated in membrane-associated vesicles concentrated at the invadopodia of tumor cells and on cell surfaces where it colocalized with integrins. Legumain was demonstrated to activate progelatinase A. Cells overexpressing Legumain possessed increased migratory and invasive activity in vitro and adopted an invasive and metastatic phenotype in vivo, inferring significance of Legumain in tumor invasion and metastasis. In addition, Legumain is expressed in both murine and human atherosclerotic lesions. The macrophage-specific expression of Legumain in vivo and ability of Legumain to induce chemotaxis of monocytes and endothelial cells in vitro suggest that Legumain may play a functional role in atherogenesis.
  • References
    • Schwarz G, et al. (2002) Characterization of legumain. Biol Chem. 383(11): 1813-6.
    • Liu C, et al. (2003) Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 63(11): 2957-64.
    • Murthy RV, et al. (2005) Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res. 11(6): 2293-9.
    • Gawenda J, et al. (2007) Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res Treat. 102(1): 1-6.
    • Clerin V, et al. (2007) Expression of the cysteine protease legumain in vascular lesions and functional implications in atherogenesis. Atherosclerosis. 201(1): 53-66.
    • Lew?“n S, et al. (2008) A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol Immunother. 57(4): 507-15.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"